NASDAQConsumer DiscretionarySpecialty RetailSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain dividend payments near $0.1 per share | A supporting condition in NATURAL HEALTH TRENDS CORP's published investment case. The stated target is Dividend per share >= $0.1 next 4 quarters. | Intact | Dividend per share falls below $0.1 next 4 quarters | Dividend per share: $0.10 per share FY2026-Q2; GAAP. Published target: Dividend per share >= $0.1 next 4 quarters. Target period is not explicitly aligned with this observation. Source published Jul 29, 20260.1 USD/share · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 61c57682-6514-4797-92d4-edcd32ecd85a. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 of last 2 quarters. Management declared and paid a quarterly dividend of $0.10 per share in 2026-Q1, down from $0.20 per share in 2025-Q4 as anticipated. Dividend payments continue but at a reduced rate, consistent with management's stated plan. Delivery assessment Oct 24, 2026 |
Improve operating income from negative levels | Operating losses are shrinking but still negative. | Broken | Operating income remains negative through FY26 | Operating income: $-643,000 FY2026-Q2; GAAP. Published target: Operating income >= $0 by FY26. Target period is not explicitly aligned with this observation. Source published Jul 29, 2026-643,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 61c57682-6514-4797-92d4-edcd32ecd85a. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Complete share repurchase of 25.5% outstanding shares | A primary condition in NATURAL HEALTH TRENDS CORP's published investment case. The stated target is Repurchase 2,935,227 shares by 2026-Q1. | Intact | Repurchased shares fall short of 2,900,000 by 2026-Q1 | Required source inputs unavailable Cannot calculate Share repurchases from the available matching source inputs. Missing inputs are not treated as zero. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 of last 2 quarters. The Board authorized resuming stock repurchases with about $16 million available as of 2026-Q2. Total cash and marketable securities declined from $21.2 million in 2026-Q1 to $18.6 million in 2026-Q2, reflecting repurchases and dividends. The trajectory shows active capital allocation via buybacks consistent with management's stated priority. Delivery assessment Oct 24, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Oct 28, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making business with a turnaround-like thesis, rather than a proven durable compounder. The multi-year view is still on watch, and recent performance has been weak relative to its industry cohort.
The valuation evidence is mixed: NHTC is described as cheap versus peers, while the model also shows a peer premium and has low confidence. The expectations gap is negative, and the pricing assessment says weak execution is reflected, but not a broader combination of expensive valuation and business turbulence.
Near term, the risk of another earnings miss is elevated after consecutive misses, and a guidance cut would add concern. Management has delivered some restructuring savings, but operating losses widened from the first to the second quarter of 2026. Repurchases and dividends continue, though cash declined and the dividend was reduced.
The near-term swing factor is whether NHTC avoids a guidance cut and improves execution after recent weak results. Over the multi-year view, progress depends on cost savings helping the business while losses narrow. Consumer Discretionary sector strength could provide a tailwind, while weaker results or guidance from sector bellwethers could remove it.
The 1-3 year thesis is cautious and depends on operating improvement, with current evidence showing partial cost-cutting progress but fragile earnings and high risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.